Hikma Pharmaceuticals (LON:HIK) Stock Price Crosses Above 200 Day Moving Average - Time to Sell?

Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 2,022.01 ($27.24) and traded as high as GBX 2,090 ($28.16). Hikma Pharmaceuticals shares last traded at GBX 2,072.87 ($27.92), with a volume of 390,402 shares changing hands.

Wall Street Analysts Forecast Growth

Several research firms have commented on HIK. JPMorgan Chase & Co. restated an "overweight" rating on shares of Hikma Pharmaceuticals in a research report on Friday, March 7th. Berenberg Bank restated a "buy" rating and issued a GBX 2,560 ($34.49) target price on shares of Hikma Pharmaceuticals in a research report on Monday, March 10th.

Hikma Pharmaceuticals Trading Down 1.2%

The company has a current ratio of 1.66, a quick ratio of 1.27 and a debt-to-equity ratio of 55.82. The stock has a market cap of £5.89 billion, a P/E ratio of 20.83, a PEG ratio of 2.38 and a beta of 0.41. The firm's 50-day simple moving average is GBX 1,958.89 and its 200 day simple moving average is GBX 2,029.86.

Insiders Place Their Bets

In other news, insider Victoria Hull sold 2,777 shares of the stock in a transaction that occurred on Tuesday, April 8th. The shares were sold at an average price of GBX 1,800 ($24.25), for a total value of £49,986 ($67,339.35). 30.54% of the stock is owned by insiders.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.